Cargando…
Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data
BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501550/ https://www.ncbi.nlm.nih.gov/pubmed/37708143 http://dx.doi.org/10.1371/journal.pone.0291244 |
_version_ | 1785106133750382592 |
---|---|
author | Nyandele, Jane Paula Kibondo, Ummi Abdul Issa, Fatuma Van Geertruyden, Jean Pierre Warimwe, George Jongo, Said Abdulla, Salim Olotu, Ally |
author_facet | Nyandele, Jane Paula Kibondo, Ummi Abdul Issa, Fatuma Van Geertruyden, Jean Pierre Warimwe, George Jongo, Said Abdulla, Salim Olotu, Ally |
author_sort | Nyandele, Jane Paula |
collection | PubMed |
description | BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI). METHODS: We evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted. RESULTS: The unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p <0.001). No correlation was observed between monocyte-to-lymphocyte ratio and RTS,S vaccine efficacy (Hazard Rate (HR):0.90, 95%CI:0.45–1.80; p = 0.77). The unadjusted efficacy of Whole Sporozoite malaria vaccine in the appended dataset was 17.6% (95%CI:10%-28.5%, p<0.001). No association between monocyte-to-lymphocyte ratio and the Whole Sporozoite malaria vaccine was found against either the prepatent period (HR = 1.16; 95%CI:0.51–2.62, p = 0.72), parasite density (rho = 0.004, p = 0.97) or multiplication rates (rho = 0.031, p = 0.80). CONCLUSION: Monocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination. |
format | Online Article Text |
id | pubmed-10501550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-105015502023-09-15 Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data Nyandele, Jane Paula Kibondo, Ummi Abdul Issa, Fatuma Van Geertruyden, Jean Pierre Warimwe, George Jongo, Said Abdulla, Salim Olotu, Ally PLoS One Research Article BACKGROUND: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI). METHODS: We evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted. RESULTS: The unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p <0.001). No correlation was observed between monocyte-to-lymphocyte ratio and RTS,S vaccine efficacy (Hazard Rate (HR):0.90, 95%CI:0.45–1.80; p = 0.77). The unadjusted efficacy of Whole Sporozoite malaria vaccine in the appended dataset was 17.6% (95%CI:10%-28.5%, p<0.001). No association between monocyte-to-lymphocyte ratio and the Whole Sporozoite malaria vaccine was found against either the prepatent period (HR = 1.16; 95%CI:0.51–2.62, p = 0.72), parasite density (rho = 0.004, p = 0.97) or multiplication rates (rho = 0.031, p = 0.80). CONCLUSION: Monocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination. Public Library of Science 2023-09-14 /pmc/articles/PMC10501550/ /pubmed/37708143 http://dx.doi.org/10.1371/journal.pone.0291244 Text en © 2023 Nyandele et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Nyandele, Jane Paula Kibondo, Ummi Abdul Issa, Fatuma Van Geertruyden, Jean Pierre Warimwe, George Jongo, Said Abdulla, Salim Olotu, Ally Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title | Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title_full | Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title_fullStr | Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title_full_unstemmed | Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title_short | Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data |
title_sort | pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: a subgroup analysis of pooled clinical trial data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501550/ https://www.ncbi.nlm.nih.gov/pubmed/37708143 http://dx.doi.org/10.1371/journal.pone.0291244 |
work_keys_str_mv | AT nyandelejanepaula prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT kibondoummiabdul prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT issafatuma prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT vangeertruydenjeanpierre prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT warimwegeorge prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT jongosaid prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT abdullasalim prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata AT olotually prevaccinationmonocytetolymphocyteratioasabiomarkerfortheefficacyofmalariacandidatevaccinesasubgroupanalysisofpooledclinicaltrialdata |